TVCM "Medicines and beyond"

  • CM Concept



    "Infectious diseases can take so much away from us."


    We are in facing the global spred of new corona virus infection.

    Still, we must never stop pursuing our goals and our dreams, and moving forward towards a brighter tomorrow.


    "At Shionogi, we’ve been discovering and delivering new products to protect you from the threat of infectious disease."


    Shionogi has set "Protect people worldwide from the threat of infectious diseases" as a material issues to create new value for customers and society, and has been providing medicines for treating infectious diseases for more than half a century.


    The Shionogi Group corporate advertisement introduces the current state of Shionogi, which aims not only to deliver therapeutic drugs but also to provide total care for infectious diseases.


    "Medicines and beyond, creating the next generation of healthcare.” Shionogi will continue to challenge.

"Medicines and beyond" movie 60sec

  • Infectious diseases can take so much away from us.

    Viruses, bacteria, fungi and parasites that cause infectious diseases.


    Invisible pathogens can infiltrate into the human body unknowingly, causing serious symptoms and sometimes even life-threatening.

  • Still, we must never stop pursuing our goals and our dreams, and moving forward towards a brighter tomorrow.

    Smallpox, epidemics, the Spanish flu, tuberculosis, malaria, and HIV, humankind has been threatened by many infectious diseases. In each case, the efforts of medical professionals and the awareness and actions of each person overcame the crisis and people continued to move forward.

  • Shionogi has been discovering and delivering new solutions to protect you from the threat of infectious disease.

    Shionogi has been working on infectious diseases for more than half a century.

    Shionogi’s involvement in the field of infectious diseases essentially began when we began importing streptomycin in the years following World War II.

    In 1959 we launched the long-acting sulfonamide Shinomin, the first proprietary product to come out of our research. The drug was used to treat patients with infectious diseases worldwide. 

    Shionogi now has been involved in infectious disease R&D for over 60 years, either independently or via strategic alliances with other companies/organizations, and we seek to continue generating new products in this field by drawing on that extensive experience in antibiotic drug discovery.

Shionogi is of service in the global battle against infectious disease, from the first in-house product through to the present day

After the discovery of penicillin, there were very few new treatments discovered for infectious diseases that were both effective and safe, and tuberculosis and pneumonia continued to top the rankings for cause of death at that time. 

Shionogi’s management team decided that, given the importance of antibiotics, the Company should move into this field as a matter of priority. Shionogi then embarked on research and development in infectious diseases. The Company poured its energies into in-house research and was rewarded with the development of its first proprietary product, Sinomin, in 1959. Sinomin was out-licensed to the Swiss company Roche and was used around the world to treat infectious diseases. Today, after more than 50 years on the market, Sinomin is still playing a vital role in healthcare, now formulated as the sulfamethoxazole and trimethoprim combination Baktar.

Many companies have withdrawn from the antibiotics market

Shionogi has developed a series of groundbreaking proprietary products to treat infectious diseases, starting with the world’s first oxacephem antibiotic Shiomarin. The number of antibiotics launched on global markets peaked in the late 1980s before starting to decline. This trend was driven by many pharmaceutical companies deciding antibiotics lacked appeal as a market, due to high development risk and the lower drug prices and shorter treatment regimens compared with anticancers and other drug types.

The decline was also exacerbated by the problem of antimicrobial resistance (AMR). To ensure doctors still have access to treatments effective against drug-resistant strains, the general consensus was that pharmaceutical companies should not pursue antibiotic sales growth.  Drugmakers also found it difficult to formulate accurate production plans because of the significant regional variation in healthcare systems for AMR and the number of patients with drug-resistant infections

Shionogi continues to invest in R&D as part of the Company’s social responsibilities

The threat posed by infectious diseases and drug-resistant bacteria is an enormous social issue for mankind. In the future, patients may lose their lives if doctors do not have access to new drugs. For this reason, Shionogi continues to invest in the discovery of new drugs to treat a wide range of infectious diseases. The Company has also taken the initiative in efforts to address AMR.

Leveraging expertise built up through many years’ experience in antimicrobial drug discovery, Shionogi will make every effort to fulfill its mission of providing treatments for infectious diseases.

1959 sulfamethoxazole, the first sulfonamide antibiotic drug discovered and developed by Shionogi
1982 moxalactam, the world’s first oxacephem antibiotic
1988 flomoxef, the world’s second oxacephem antibiotic
1992 ceftibuten, new oral cephem antibiotics
1997 cefcapene, new oral cephem antibiotics
2005 doripenem, a new carbapenem antibiotic
2010 peramivir, new anti-HIV agent
2014 dolutegravir, new oral anti-HIV agent
2018 baloxavir, new oral anti-influenza virus agent
2019 cefiderocol, new ciderophore cephalosporin antibiotics
2020 Cabotegravir, long-acting HIV injection
  • Aiming at total care for infectious diseases

    "Let's sing together. The song of our future."

    Shionogi considers protecting people worldwide from the threat of infectious disease to be a pressing social issue. The company will only become a leading company in infectious diseases once we are in a position to provide solutions covering all stages of infectious disease. Based on this concept, we aim to provide “total care for infectious diseases” that starts with R&D into agents to treat infectious diseases, and also includes the earlier stages of raising awareness through disease education, prevention, and diagnosis through to the final stages including control of disease severity and saving lives.

Three care for total care for infectious diseases, and digital utilization

Daily Care

・Analysis of infectious disease trends

・Development of vaccines for prevention

・Development of early detection / diagnosis approach

Daily Care

Intensive Care

Research and development and provision of 

・ Medicine that quickly reduces pathogens that have invaded the body

・ Medicine that quickly improves the symptoms of infectious diseases

・ Medicine that control of disease severity and saving lives


Intensive Care

After Care

Providing information to keep an eye on the progress of recovery and to stay close until daily life returns

After Care

Utilizing digital teqnology

With the use of big data, AI, and ICT, things that could not be done before are becoming commonplace.

In addition to engaginf in the efficiency of research, development, manufacturing, and promtion of innovative medicines which is our strength, Shionogi pursues the possibilities brought about by information technology,  to develop of digital medicine and apps for treatment.

We aim to create new healthcare solutions and contribute to people's problems from the perspective of total care, including pre-illness, prevention, and diagnosis.

Introduction of Shionogi's efforts for infectious diseases

  • Commitment to Fight COVID-19

       In order to realize total care from prevention to treatment of COVID-19, place related projects as the top priority of the entire company and put solutions into practical use in a timely manner with our partners.

    Learn more
  • Address the problem of antimicrobial resistance (AMR)

    Antimicrobial resistance (AMR) is a global threat with potentially devastating consequences to those infected with resistant pathogens and high direct and indirect cost to society. In the future, lack of effective antibiotics could make routine medical interventions extremely dangerous and make other more complex interventions and procedures impossible.

    Learn more
  • What We Are Focusing On

    We are focusing on infectious diseases and pain/CNS disorders as core therapeutic areas to create innovative medicines. We are also studying on geriatric diseases and other frontier areas.